GSK: Profits, Patents and Patients: Access to Medicines

N. Craig Smith () and Dawn Jarisch
Additional contact information
N. Craig Smith: INSEAD
Dawn Jarisch: INSEAD

Chapter 8 in Managing Sustainable Business, 2019, pp 145-170 from Springer

Abstract: Abstract On April 22nd 2014, after a difficult year in which GlaxoSmithKline (GSK) had been accused of bribery in China and fined $3 billion by American regulators for marketing malpractice in the US, the pharmaceutical company announced a complex three-part restructuring deal with Swiss giant Novartis. The deal, one of a slew of multibillion-dollar deals in the global pharmaceutical industry, would allow GSK to focus on four key business areas – HIV, vaccines, respiratory conditions and consumer healthcare. It was seen as a win-win deal, offering both companies economies of scale that were increasingly vital for ‘big pharma’. Analysts believed it would ‘unlock significant shareholder value’, not least because it would allow GSK to return £4 billion to investors through a B share scheme.

Keywords: Global Alliance For Vaccines And Immunization (GAVI); Least Developed Countries (LDCs); Trade-Related Aspects Of Intellectual Property Rights (TRIPS); TRIPS Agreement; ViiV Healthcare (search for similar items in EconPapers)
Date: 2019
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-94-024-1144-7_8

Ordering information: This item can be ordered from
http://www.springer.com/9789402411447

DOI: 10.1007/978-94-024-1144-7_8

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().